Antibody-drug conjugates are reshaping the landscape of oncology by offering highly targeted cancer therapies with enhanced specificity, reduced toxicity and improved efficacy. However, the development of antibody-drug conjugates remains complex, with challenges that include optimizing drug delivery, overcoming resistance and identifying the right patient populations for treatment.
This webinar will explore how recent advancements in bioconjugation technology and multi-omics approaches are driving the next generation of antibody-drug conjugates from preclinical evaluation to clinical application.
Attendees will gain key insights into how cutting-edge preclinical models, such as patient-derived xenografts (PDX) and 3D organoids, can more accurately reflect human tumor biology and resistance mechanisms. By integrating these models into the drug development process, researchers can gain a deeper understanding of antibody-drug conjugates’ efficacy, optimize therapeutic design and accelerate the transition from preclinical to clinical stages.
This webinar will also highlight the critical role of multi-omics approaches in the development of antibody-drug conjugates. Advanced bioinformatics tools, combined with proteomics and genomics data, allow for the identification of potential biomarkers, enabling precise patient stratification and enhancing clinical trial success. This data-driven approach not only improves therapeutic outcomes of antibody-drug conjugates but also opens up new avenues for personalized medicine.
The speakers will also discuss strategies for target and indication identification, focusing on how antibody-drug conjugates can be effectively combined with immuno-oncology therapies. These combination strategies are becoming increasingly important in the fight against cancer, as they offer the potential to overcome resistance and enhance the overall therapeutic effect. The expert speakers will share real-world examples of how these approaches are being applied in current drug development pipelines, offering valuable insights for pharmaceutical and biotech professionals.
Whether early-stage antibody-drug conjugates’ discovery, preclinical evaluation or clinical trial design, this webinar will provide actionable knowledge to help overcome key challenges and accelerate the development of novel antibody-drug conjugate-based therapies.
Register for this webinar today to understand how innovative preclinical models and advanced multi-omics approaches can enhance the development of antibody-drug conjugates, streamline clinical success and unlock the potential for personalized cancer treatments. Don’t miss this opportunity to learn from industry experts and stay at the forefront of oncology drug development!
Speaker
Peng Wang, PhD, Executive Director, Scientific Operations, Crown Bioscience
Peng Wang is responsible for cell line construction, organoid development, in vitro assays and antibody discovery at Crown Bioscience. Dr. Wang holds a PhD in Biological Sciences from the University of Delaware and completed a postdoctoral fellowship in Immunology at the University of Pennsylvania’s Perelman School of Medicine.
Dr. Wang formerly worked at Roche (China) and WuXi AppTec, with over 15 years of experience in biomedical research and drug development.
Message PresenterWho Should Attend?
This webinar will appeal to professionals from the pharmaceutical and biotech industries, as well as academic researchers in oncology drug development:
- Pharma/Biotech Scientists working on ADCs, biologics, drug discovery and preclinical testing
- Clinical development teams involved in clinical trials, patient stratification and biomarker validation
- Immuno-Oncology experts focused on combination therapies, particularly integrating ADCs with immunotherapies
- Bioinformaticians
What You Will Learn
Attendees will learn about:
- How leveraging the industry’s largest collection of in vivo PDX and in vitro 3D organoids can revolutionize preclinical antibody-drug conjugate evaluation and overcome resistance challenges
- How advanced bioinformatics and multi-omics approaches can unveil therapeutic efficacy, pinpoint responsive patient populations and identify biomarkers for precise clinical applications
- How immuno-oncology preclinical services can support target validation, indication identification and innovative combination therapy approaches for maximum impact
Xtalks Partner
Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 12 facilities across the US, Europe, and Asia.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account